NCT03504397 2026-02-13SpotlightAstellas Pharma IncPhase 3 Active not recruiting565 enrolled 63 charts 1 FDA
NCT03653507 2026-02-06GLOWAstellas Pharma IncPhase 3 Active not recruiting507 enrolled 65 charts 1 FDA
NCT02864992 2025-12-23Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)EMD SeronoPhase 2 Active not recruiting337 enrolled 13 charts 2 FDA
NCT03093116 2025-07-10TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA